ClinicalTrials.gov
public full text
Public Domain
Glycine vs Placebo for the Schizophrenia Prodrome
Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Facilitation of NMDA Receptor Function in Patients With Schizophrenia and Co-morbid Alcoholism#980298
- Adjunctive Glycine for Obsessive Compulsive Disorder#1008113
- N-methylglycine (Sarcosine) Treatment for Depression#914050
- Native architecture, allosteric modulation and gating mechanism of glycine-dependent NMDA receptors#127546
- Occipital gamma-aminobutyric acid and glutamate-glutamine alterations in major depressive disorder: An mrs study and meta-analysis#715389
Record · ID 1183772
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive